Show Summary Details
Page of

Assessment 

Assessment
Chapter:
Assessment
Author(s):

Andrew Davies

DOI:
10.1093/med/9780198840480.003.0003
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 13 July 2020

Successful management of breakthrough pain depends on adequate assessment and adequate re-assessment. The assessment of pain primarily depends on basic clinical skills, that is, taking a detailed history and performing a thorough examination. Inadequate assessment may lead to ineffective or even inappropriate treatment. The objectives of assessment are to determine the aetiology and pathophysiology of the pain, and factors that indicate or contraindicate particular treatments. It is important to differentiate patients with uncontrolled background pain experiencing transient exacerbations of that pain, from patients with controlled background pain experiencing episodes of breakthrough pain. Inadequate reassessment may lead to the continuance of ineffective or inappropriate treatment. A number of different tools have been developed for the assessment of cancer-related pain. Those focusing on breakthrough pain include: the Breakthrough Pain Questionnaire, the Alberta Breakthrough Pain Assessment Tool, and the Breakthrough Pain Assessment Tool.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.